|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002395,
umls-concept:C0030705,
umls-concept:C0031268,
umls-concept:C0031809,
umls-concept:C0032743,
umls-concept:C0205390,
umls-concept:C0332293,
umls-concept:C0392747,
umls-concept:C0443172,
umls-concept:C1550025,
umls-concept:C1869457,
umls-concept:C2346689,
umls-concept:C2603343,
umls-concept:C2698328
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-3-19
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer's disease.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-(4'-(methylamino)phenyl)-6-hydroxy...,
http://linkedlifedata.com/resource/pubmed/chemical/Amyloid beta-Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Aniline Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/bapineuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1474-4465
|
|
pubmed:author |
pubmed-author:BarakosJeromeJ,
pubmed-author:BlackRonaldR,
pubmed-author:BlennowKajK,
pubmed-author:BrooksDavid JDJ,
pubmed-author:BullockRogerR,
pubmed-author:FoxNick CNC,
pubmed-author:GreggKeith MKM,
pubmed-author:GrundmanMichaelM,
pubmed-author:KlunkWilliam EWE,
pubmed-author:KollerMartinM,
pubmed-author:LiuEnchiE,
pubmed-author:MathisChester ACA,
pubmed-author:OkelloAren AAA,
pubmed-author:RinneJuha OJO,
pubmed-author:Rodriguez Martinez de LianoSofiaS,
pubmed-author:RossorMartin NMN,
pubmed-author:SchenkDaleD
|
|
pubmed:copyrightInfo |
2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
363-72
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20189881-Aged,
pubmed-meshheading:20189881-Alzheimer Disease,
pubmed-meshheading:20189881-Amyloid beta-Peptides,
pubmed-meshheading:20189881-Aniline Compounds,
pubmed-meshheading:20189881-Antibodies, Monoclonal,
pubmed-meshheading:20189881-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20189881-Brain,
pubmed-meshheading:20189881-Brain Mapping,
pubmed-meshheading:20189881-Dose-Response Relationship, Drug,
pubmed-meshheading:20189881-Double-Blind Method,
pubmed-meshheading:20189881-Female,
pubmed-meshheading:20189881-Humans,
pubmed-meshheading:20189881-Immunologic Factors,
pubmed-meshheading:20189881-Male,
pubmed-meshheading:20189881-Positron-Emission Tomography,
pubmed-meshheading:20189881-Severity of Illness Index,
pubmed-meshheading:20189881-Thiazoles,
pubmed-meshheading:20189881-Time Factors,
pubmed-meshheading:20189881-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
|
|
pubmed:affiliation |
Turku PET Centre and Clinical Research Services Turku, University of Turku and Turku University Hospital, Turku, Finland. juha.rinne@tyks.fi
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
